

Our ref: FOI 1437

17th February 2023

FOI 1437 Response

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab

• Adalimumab - Humira	31
• Adalimumab Biosimilar	207
• Apremilast	0
• Bimekizumab	0
• Brodalumab	9
• Certolizumab	6
• Dimethyl fumarate	0
• Etanercept - Enbrel	<5
• Etanercept Biosimilar	<5
• Guselkumab	57
• Infliximab - Remicade	0
• Infliximab Biosimilar	6
• Ixekizumab	72
• Risankizumab	39

*Currently on treatment

Part2

- Secukinumab
- Tildrakizumab
- Ustekinumab

• Secukinumab	30
• Tildrakizumab	9
• Ustekinumab	33

Q2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Infliximab - Remicade
- Infliximab Biosimilar
- Secukinumab
- Ustekinumab

• Adalimumab - Humira	21
• Adalimumab Biosimilar	29
• Infliximab - Remicade	0
• Infliximab Biosimilar	<5
• Secukinumab	<5
• Ustekinumab	0

Part3

Q3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

Ciclosporin	17
Methotrexate	93
S/C Methotrexate	7

This data has been captured from nurse led activity. This information is not held under the Medical Clinics.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net